Estrogen Receptor
New driver of breast cancer discovered
December 05, 2013As cholesterol is metabolized, a potent stimulant of breast cancer is created—one that fuels estrogen receptor (ER)-positive breast cancers, according to new research.
Luminal breast tumors have enhanced response to antiestrogen therapy
September 11, 2013The luminal breast cancer subtype has enhanced expression of the ERBB3 oncogene, and depleting the ERBB3 protein with an antibody promotes cancer cell death and decreases tumor growth in vitro, according to a new study.
BH3 mimetics improved tamoxifen therapy in breast cancer
July 22, 2013The addition of BH3 mimetics to standard tamoxifen treatment improved the effectiveness of hormone therapy in luminal B cancers, an aggressive subtype of ER-positive breast cancer.
Osteoporosis drug stops growth of breast cancer cells, including resistant cells
July 04, 2013A drug approved in Europe to treat osteoporosis has been shown to stop the growth of breast cancer cells, according to a new study.
Fat-metabolism genes may predict breast cancer down to the ER subtype
April 03, 2013Lipid-metabolism genes are potential biomarkers of estrogen-receptor (ER)-specific breast cancer risk, researchers have found.
Model underestimates breast cancer risk for some African-American women
March 06, 2013A breast cancer risk model for African-American women underpredicted individual risk and risk of estrogen receptor (ER)-negative disease.
Clinical benefit seen when investigational agent is combined with letrozole
December 14, 2012The combination of the investigational agent PD 0332991 and letrozole significantly improved median progression-free survival in patients with advanced estrogen receptor-positive breast cancer.
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |